Clinical trial • Phase III • Other

NNC0487-0111 for Obesity

Phase III trial of NNC0487-0111 for Obesity. 120 participants.

Overview

Trial Therapeutic Area
Other
Trial Disease
Obesity
Trial Stage
Phase III

Key dates

Initial CTIS Submission Date
14-01-2026
First CTIS Authorization Date
13-03-2026

Trial design

Phase III trial across 1 site in Germany.

Target Sample Size
120

Recruitment

Planned Sample Size
120
Recruitment Window Months
21

Geography

Total Number Of Sites
1
Total Number Of Participants
120

Germany

Earliest CTIS Part Ii Submission Date
25-02-2026
Latest Decision Or Authorization Date
13-03-2026
Processing Time Days
16
Number Of Sites
1
Number Of Participants
120

Sites

Site Name
Klinikum Westend Haus 31, Spandauer Damm 130, Charlottenburg
Department Name
Parexel Early Phase Unit Berlin
Contact Person Name
Javier Hernandez

Sponsor

Primary sponsor

Full Name
Novo Nordisk A/S
Organisation Type
Pharmaceutical company
Country Of Registered Address
Denmark

Contract research organisations

Name
PAREXEL International GmbH
Responsibilities
Listed as trial site organisation and contact (site management / site contact); contact person: Javier Hernandez, email javier.hernandezbuenabad@parexel.com

Investigational products

Investigational Product Name
NNC0487-0111

Related trials

Other published trials that may interest you.